Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 5, 2026, 5:34 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 122 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: GSK1120212 (trametinib) Clear all
Completed Phase 2 Interventional Results available

An Open-Label Phase II Study of the Combination of GSK2118436 and GSK1120212 in Patients With Metastatic Melanoma Which is Refractory or Resistant to BRAF Inhibitor

NCT01619774
View directory record Official record
Conditions
Melanoma
Interventions
GSK2118436, GSK1120212
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
16 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 12, 2016 · Synced Oct 5, 2026, 5:34 AM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare Cancers

NCT02034110
View directory record Official record
Conditions
Cancer
Interventions
Dabrafenib, Trametinib
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
206 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
8
States / cities
Little Rock, Arkansas • Santa Monica, California • Bethesda, Maryland + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2023 · Synced Oct 5, 2026, 5:34 AM EDT
Completed Phase 1 Interventional

A Study of the GSK MEK Inhibitor GSK1120212 and Everolimus in Cancer Subjects

NCT00955773
View directory record Official record
Conditions
Cancer
Interventions
GSK1120212 plus everolimus
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
2
States / cities
Nashville, Tennessee • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Nov 9, 2017 · Synced Oct 5, 2026, 5:34 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Testing the Addition of Navitoclax to the Combination of Dabrafenib and Trametinib in People Who Have BRAF Mutant Melanoma

NCT01989585
View directory record Official record
Conditions
Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Malignant Solid Neoplasm, Metastatic Melanoma, Unresectable Melanoma
Interventions
Biopsy Procedure, Biospecimen Collection, Computed Tomography, Dabrafenib, Echocardiography Test, Laboratory Biomarker Analysis, Magnetic Resonance Imaging, Multigated Acquisition Scan, Navitoclax, Pharmacological Study, Trametinib
Procedure · Drug · Other + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2027
U.S. locations
49
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Los Angeles, California + 37 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Oct 5, 2026, 5:34 AM EDT
Completed Phase 1 Interventional

A Study to Determine the Relative Bioavailability of the MEK Inhibitor, Trametinib, in Subjects With Solid Tumor Malignancies

NCT01725100
View directory record Official record
Conditions
Cancer
Interventions
GSK1120212B (Standard DMSO content), GSK1120212B (Lower DMSO content)
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
4
States / cities
Goodyear, Arizona • Scottsdale, Arizona • Sarasota, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 13, 2017 · Synced Oct 5, 2026, 5:34 AM EDT
Completed Phase 1 Interventional

A Study of the Safety and Activity of the MEK Inhibitor Given Together With the AKT Inhibitor to Patients With Multiple Myeloma or Solid Tumor Cancers

NCT01476137
View directory record Official record
Conditions
Cancer
Interventions
GSK1120212, GSK2110183
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
335 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
2
States / cities
Dallas, Texas • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Nov 13, 2017 · Synced Oct 5, 2026, 5:34 AM EDT
Terminated Phase 2 Interventional Results available

Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Acute Myeloid Leukemia

NCT01907815
View directory record Official record
Conditions
Recurrent Adult Acute Myeloid Leukemia, Untreated Adult Acute Myeloid Leukemia
Interventions
Akt Inhibitor GSK2141795, Laboratory Biomarker Analysis, Trametinib
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
3
States / cities
Chicago, Illinois • Baltimore, Maryland • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 6, 2018 · Synced Oct 5, 2026, 5:34 AM EDT
Completed Phase 2 Interventional Results available

LCCC 1128: Open Label Phase II Trial of the BRAF Inhibitor (Dabrafenib) and the MEK Inhibitor (Trametinib) in Unresectable Stage III and Stage IV BRAF Mutant Melanoma; Correlation of Resistance With the Kinome and Functional Mutations

NCT01726738
View directory record Official record
Conditions
Stage III Melanoma, Stage IV Melanoma, Unresectable Melanoma, BRAF Mutant Melanoma
Interventions
BRAF inhibitor dabrafenib and MEK inhibitor trametinib
Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 23, 2020 · Synced Oct 5, 2026, 5:34 AM EDT
Active, not recruiting Phase 2 Interventional

Trametinib in Treating Patients With Progressive Metastatic Hormone-Resistant Prostate Cancer

NCT02881242
View directory record Official record
Conditions
Hormone-Resistant Prostate Cancer, Metastatic Prostate Carcinoma, Recurrent Prostate Carcinoma, Stage IV Prostate Cancer
Interventions
Laboratory Biomarker Analysis, Quality-of-Life Assessment, Trametinib
Other · Drug
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 1, 2023 · Synced Oct 5, 2026, 5:34 AM EDT
Completed Phase 1 Interventional

SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors

NCT03434262
View directory record Official record
Conditions
Anaplastic Astrocytoma, Anaplastic Ependymoma, Anaplastic Ganglioglioma, Anaplastic Meningioma, Anaplastic Oligodendroglioma, Pleomorphic Xanthoastrocytoma, Anaplastic, Atypical Teratoid/Rhabdoid Tumor, Brain Cancer, Brain Tumor, Central Nervous System Neoplasms, Choroid Plexus Carcinoma, CNS Embryonal Tumor With Rhabdoid Features, Ganglioneuroblastoma of Central Nervous System, CNS Tumor, Embryonal Tumor of CNS, Ependymoma, Glioblastoma, Glioma, Glioma, Malignant, Medulloblastoma, Medulloblastoma; Unspecified Site, Medulloepithelioma, Neuroepithelial Tumor, Neoplasms, Neoplasms, Neuroepithelial, Papillary Tumor of the Pineal Region (High-grade Only), Pediatric Brain Tumor, Pineal Parenchymal Tumor of Intermediate Differentiation (High-grade Only), Pineoblastoma, Primitive Neuroectodermal Tumor, Recurrent Medulloblastoma, Refractory Brain Tumor, Neuroblastoma. CNS, Glioblastoma, IDH-mutant, Glioblastoma, IDH-wildtype, Medulloblastoma, Group 3, Medulloblastoma, Group 4, Glioma, High Grade, Neuroepithelial Tumor, High Grade, Medulloblastoma, SHH-activated and TP53 Mutant, Medulloblastoma, SHH-activated and TP53 Wildtype, Medulloblastoma, Chromosome 9q Loss, Medulloblastoma, Non-WNT Non-SHH, NOS, Medulloblastoma, Non-WNT/Non-SHH, Medulloblastoma, PTCH1 Mutation, Medulloblastoma, WNT-activated, Ependymoma, Recurrent, Glioma, Recurrent High Grade, Glioma, Recurrent Malignant, Embryonal Tumor, NOS, Glioma, Diffuse Midline, H3K27M-mutant, Embryonal Tumor With Multilayered Rosettes (ETMR), Ependymoma, NOS, WHO Grade III, Ependymoma, NOS, WHO Grade II, Medulloblastoma, G3/G4, Ependymoma, RELA Fusion Positive
Interventions
Gemcitabine, ribociclib, sonidegib, trametinib, filgrastim
Drug · Biological
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
1 Year to 39 Years
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated May 31, 2024 · Synced Oct 5, 2026, 5:34 AM EDT
Completed Phase 3 Interventional Results available

GSK1120212 vs Chemotherapy in Advanced or Metastatic BRAF V600E/K Mutation-positive Melanoma

NCT01245062
View directory record Official record
Conditions
Melanoma
Interventions
GSK1120212, Chemotherapy
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
322 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
13
States / cities
Tucson, Arizona • Fort Myers, Florida • Athens, Georgia + 10 more
Source: ClinicalTrials.gov public record
Updated Apr 5, 2018 · Synced Oct 5, 2026, 5:34 AM EDT
Completed Phase 1 Interventional

Trametinib in Combination With Sorafenib in Patients With Advanced Hepatocellular Cancer

NCT02292173
View directory record Official record
Conditions
Hepatocellular Cancer, Liver Cancer
Interventions
Trametinib, Sorafenib
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jun 10, 2021 · Synced Oct 5, 2026, 5:34 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Trametinib With or Without GSK2141795 in Treating Patients With Metastatic Uveal Melanoma

NCT01979523
View directory record Official record
Conditions
Recurrent Uveal Melanoma, Stage IV Uveal Melanoma AJCC v7
Interventions
Laboratory Biomarker Analysis, Pharmacological Study, Trametinib, Uprosertib
Other · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2027
U.S. locations
5
States / cities
Atlanta, Georgia • New York, New York • Nashville, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Oct 5, 2026, 5:34 AM EDT
Completed Phase 1 Interventional

Open-label Study to Investigate the Safety, PK, and Pharmacodynamics of GSK1120212 in Subjects With Solid Tumors or Lymphoma

NCT00687622
View directory record Official record
Conditions
Solid Tumours
Interventions
GSK1120212
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
206 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
12
States / cities
Scottsdale, Arizona • Aurora, Colorado • Fort Myers, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Nov 13, 2017 · Synced Oct 5, 2026, 5:34 AM EDT
Completed Phase 1 Interventional

A Study to Investigate Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of BKM120 Plus GSK1120212 in Selected Advanced Solid Tumor Patients

NCT01155453
View directory record Official record
Conditions
Advanced and Selected Solid Tumors
Interventions
BKM120, GSK1120212
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
2
States / cities
Los Angeles, California • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 9, 2020 · Synced Oct 5, 2026, 5:34 AM EDT
Completed Phase 1 Interventional

Safety, Pharmacokinetics (PK) of AKT and MEK Combination

NCT01138085
View directory record Official record
Conditions
Cancer
Interventions
GSK1120212, GSK2141795
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
10
States / cities
Aurora, Colorado • New Haven, Connecticut • Boston, Massachusetts + 6 more
Source: ClinicalTrials.gov public record
Updated Nov 13, 2017 · Synced Oct 5, 2026, 5:34 AM EDT
Completed Phase 3 Interventional Results available

Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma

NCT01597908
View directory record Official record
Conditions
Melanoma
Interventions
Dabrafenib, Vemurafenib, Trametinib
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
704 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
36
States / cities
Birmingham, Alabama • Gilbert, Arizona • Beverly Hills, California + 30 more
Source: ClinicalTrials.gov public record
Updated Feb 24, 2021 · Synced Oct 5, 2026, 5:34 AM EDT
Completed Phase 2 Interventional Results available

Study of Selective BRAF Kinase Inhibitor Dabrafenib Monotherapy Twice Daily and in Combination With Dabrafenib Twice Daily and Trametinib Once Daily in Combination Therapy in Subjects With BRAF V600E Mutation Positive Metastatic (Stage IV) Non-small Cell Lung Cancer.

NCT01336634
View directory record Official record
Conditions
Cancer
Interventions
Dabrafenib, Trametinib
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
177 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2021
U.S. locations
15
States / cities
Los Angeles, California • Orange, California • Aurora, Colorado + 11 more
Source: ClinicalTrials.gov public record
Updated Apr 4, 2022 · Synced Oct 5, 2026, 5:34 AM EDT
Completed Phase 1 Interventional

Safety and Tolerability Study of GSK1120212, a MEK Inhibitor, in Combination With Docetaxel, Erlotinib, Pemetrexed, Pemetrexed + Carboplatin, Pemetrexed + Cisplatin, or Nab-Paclitaxel

NCT01192165
View directory record Official record
Conditions
Cancer
Interventions
Trametinib (GSK1120212), Docetaxel, Erlotinib, Pemetrexed, Carboplatin, nab-Paclitaxel, Cisplatin
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
169 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
13
States / cities
Scottsdale, Arizona • Duarte, California • Sacramento, California + 10 more
Source: ClinicalTrials.gov public record
Updated Nov 13, 2017 · Synced Oct 5, 2026, 5:34 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Testing Trametinib and Dabrafenib as a Potential Targeted Treatment in Cancers With BRAF Genetic Changes (MATCH-Subprotocol H)

NCT04439292
View directory record Official record
Conditions
Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Multiple Myeloma
Interventions
Dabrafenib Mesylate, Trametinib Dimethyl Sulfoxide
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 12, 2026 · Synced Oct 5, 2026, 5:34 AM EDT
Completed Phase 1 Interventional

A Rollover Study to Provide Continued Treatment With GSK2118436 to Subjects With BRAF Mutation-Positive Tumors

NCT01231594
View directory record Official record
Conditions
Cancer
Interventions
GSK2118436, GSK1120212, Other approved anti-cancer agent
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
214 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
25
States / cities
Goodyear, Arizona • Scottsdale, Arizona • Tucson, Arizona + 19 more
Source: ClinicalTrials.gov public record
Updated Mar 22, 2019 · Synced Oct 5, 2026, 5:34 AM EDT
Active, not recruiting Phase 1 Interventional

A Study of Dabrafenib and/or Trametinib in Patients With Relapsed and/or Refractory Multiple Myeloma

NCT03091257
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Dabrafenib, Trametinib
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
2
States / cities
Boston, Massachusetts • Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 31, 2026 · Synced Oct 5, 2026, 5:34 AM EDT
Withdrawn Phase 2 Interventional

Dabrafenib and Trametinib in Treating Patients With Erdheim Chester Disease With BRAF V600 Mutations

NCT03794297
View directory record Official record
Conditions
Erdheim-Chester Disease
Interventions
Dabrafenib Mesylate, Quality-of-Life Assessment, Questionnaire Administration, Trametinib Dimethyl Sulfoxide
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 17, 2021 · Synced Oct 5, 2026, 5:34 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Testing Trametinib as a Potential Targeted Treatment in Cancers With NF1 Genetic Changes (MATCH-Subprotocol S1)

NCT04439318
View directory record Official record
Conditions
Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Multiple Myeloma
Interventions
Trametinib Dimethyl Sulfoxide
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 17, 2026 · Synced Oct 5, 2026, 5:34 AM EDT